Shokubun Co., Ltd. (9969)
Market Closed
2 Oct, 06:00 AM
JPX 
¥
235. 00
0
0%
¥
- Market Cap
- P/E Ratio
- Div Yield
2,800 Volume
0 Eps
¥ 235
Previous Close Want to track 9969 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
9969 closed Friday higher at ¥235, an increase of 0% from Thursday's close, completing a monthly decrease of -1.2605% or -¥3. Over the past 12 months, 9969 stock lost -7.1146%.
9969 is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Shokubun Co., Ltd. has completed 4 stock splits, with the recent split occurring on Apr 01, 2008.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
9969 Chart
Shokubun Co., Ltd. (9969) FAQ
What is the stock price today?
The current price is ¥235.00.
On which exchange is it traded?
Shokubun Co., Ltd. is listed on JPX.
What is its stock symbol?
The ticker symbol is 9969.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Shokubun Co., Ltd. ever had a stock split?
Shokubun Co., Ltd. had 4 splits and the recent split was on Apr 01, 2008.
Shokubun Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Jisong Cui Ph.D. CEO | JPX Exchange | JP3369300003 ISIN |
| China Country | 1,176 Employees | - Last Dividend | - Last Split | - IPO Date |
InnoCare Pharma Ltd. is a leading biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer and autoimmune diseases. Headquartered in Beijing, China, InnoCare Pharma plays a significant role in the healthcare sector by advancing innovative treatments that address unmet medical needs. The company's robust pipeline emphasizes targeted therapies and small molecule drugs, aiming to improve patient outcomes with effective and safe medical solutions. InnoCare Pharma's operations span research and development, clinical trials, and eventual product commercialization, impacting both domestic and international markets. A cornerstone of its strategy is leveraging strategic partnerships and cutting-edge technology to accelerate drug discovery processes and broaden its therapeutic portfolio. Through its commitment to high-quality innovation, InnoCare Pharma contributes significantly to the biotech industry, positioning itself as a vital player in addressing pressing global health challenges. Its extensive research initiatives and collaborations underscore its market significance, aimed at paving the way for breakthroughs in the treatment of serious diseases.
Contact Information
Address: Building 8
Phone: 86 10 6660 9999
Website: https://www.innocarepharma.com
2026 © Marketlog. All Rights Reserved.
